The metamorphosis of emerging markets into markets of global importance is drawing ever more corporate attention. Among these markets are the BRIC nations, which are comparable in size to their mature western counterparts. This grouping of four different countries under the same banner reflects a somehow similar state in their development but masks their individual differences and the challenges faced by each nation. Their transformation into global markets has not followed a predefined template, which led to different models of infrastructure, reform and reimbursement. Understanding these local variations is the key into defining market access strategies for companies willing to enter those markets.

The Middle East North Africa region (MENA) is also at a crossroads and is expected to encounter sustainable growth in the medium to long term. Despite recurring political unrests, the market is becoming increasingly attractive. Healthcare reforms in these countries over the next few years could unleash the region's economic potential.

In 2014, Universal Medica together with its trusted partners will present for the first time a global cartography of opportunities in these regions unravelling more than 4 years of data collection and analysis for drugs, vaccines, medical devices and medical technologies.

In the afternoon, we will host specific workshops on each of the BRIC markets (Brazil, China, Russia, and India) and the MENA region to review local specificities in detail: pricing & reimbursement, safety & compliance regulations concerning imported drugs.

2:00 - 3:30 pm - CAPTURING THE BRAZILIAN PHARMA OPPORTUNITY
Global companies are currently missing a significant opportunity to make profits which would serve a big part of the country to grow strong and fast.

2:00 - 3:30 pm WHAT IS THE NEXT STEP FOR THE RUSSIAN PHARMA MARKET?
With competition and regulation increasing drastically in a fast growing market, companies face new challenges and must be better prepared.

4:00 - 5:30 pm INNOVATING IN CHINA'S PHARMA MARKET
China's pharmaceutical industry is entering a critical period of transformation as it is losing its traditional competitiveness, such as fares, and is also facing a sluggish international market, especially in Europe and the United States.

4:00 - 5:30 pm ROADMAPPING THE FUTURE OF THE INDIAN PHARMA MARKET
Expertise in generics, vaccines and a considerable manufacturing capactity, India's industry could prove either a powerful partner or a competitor. What are the stakes in this sophisticated pharma industry?

You can also be part of high quality networking opportunities during coffee breaks and the seated lunch: exchange with the best of industry experts, market access consultants and influential payers.

For more information and registration, please visit our website: http://www.lifescience-outlook.com/emergingmarketaccess/

If you want to become a partner or a speaker of the 5th Emerging Market Access Conference, contact us by mail to: isabelle.levasseur@universalmedica.com or call us on +33 (0)1 41 12 27 85.